Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel (ANTARCTIC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by Assistance Publique - Hôpitaux de Paris
Sponsor:
Collaborators:
Eli Lilly and Company
Daiichi Sankyo Inc.
Allies in Cardiovascular Trials Initiatives and Organized Networks:ACTION
Accumetrics, Inc.
Stentys
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT01538446
First received: February 20, 2012
Last updated: February 24, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2017
  Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
No publications provided by Assistance Publique - Hôpitaux de Paris

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):